Welcome

Pre-Open

RegMed Investors’ (RMi) pre-open: Monthly equity, index, and cash-settled currency options expiration date and PM settled index options cease trading.

May 16, 2025

Share pricing Is a journey, without a destination lately

Traveling to a BLA is arriving in the promised land, that’s if we can shoulder the road strewn with dollar investments

And then, a drug is not home, it must be accepted for reimbursement – another patience journey

Earnings:

Solid Biosciences (SLDB) net loss of -$39.28 M or -$0.59 per shares, 0 revenue, cash position of $306.9 M and a runway until 1H/27

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Out and About

RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M

May 13, 2025

SGMO is trading at $0.449 down -$0.2967 or -39.7%

Cantor is acting as sole book-running manager for the offering.

Closing Bell

RegMed Investors (RMi) Closing Bell: Cover, cover

May 16, 2025

A session of exercise, purchase, sell or letting the option contract expire worthless; your speculative purpose

On options expiration Friday

Week to date, the S&P 500 is up +5.3%, the Dow +3.4% and the Nasdaq jumped +0.52%.

Earnings:

Precigen (PGEN) Net loss of -$54.2 M or -$0.18, revenue of $300 K, cash of $81 M in cash with a 2026 runway.

Never leave an investor uninformed!

Research Notes

RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M

May 13, 2025

SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB) Chronicles: Yet another "screw job" for/on investors ... "wanting to effect a reverse split of its outstanding common stock" in its recent proxy statement filing!!

April 28, 2025

Newest 4/28/25: NO runway, barely any cash position; No partner, NO clinical data as trial falters yet the salaries and bonuses of CEO and MNGT team are OUTSTANDING and for WHAT? Is Beijing, China coming to the rescue again, NOT if President Trump has a say! Newer: Banging the drum for a Ponzi scheme designation (not the first time, maybe the 25th) as share pricing jumps +$0.03 with 3,273 shares traded on 4/25/25 ... Who's buying a falling knife ... fork and spoon after barely if any trading volume for months -- DST Capital? New: On April 11, 2025, Marcum LLP (their accountants) informed Harvard Apparatus Regenerative Technology (OTCQB: HRGN) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 11, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm. Marcum’s LLP had reported the addition of a paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. Following a MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? Under the Holding Foreign Companies Accountable Act, the SEC can ban foreign companies from trading ..." Wall Street Journal, 4/21/25 ... "Many investors would opt to SELL their stakes in Chinese firms if they are delisted"

Beam Therapeutics (BEAM) an offering of 16,151,686 shares priced at $28.48 per share

March 10, 2025

including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525

Research Notes

May 13, 2025 RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering. April 28, 2025 RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB) Chronicles: Yet another "screw job" for/on investors ... "wanting to effect a reverse split of its outstanding common stock" in its recent proxy statement filing!! Newest 4/28/25: NO runway, barely any cash position; No partner, NO clinical data as trial falters yet the salaries and bonuses of CEO and MNGT team are OUTSTANDING and for WHAT? Is Beijing, China coming to the rescue again, NOT if President Trump has a say! Newer: Banging the drum for a Ponzi scheme designation (not the first time, maybe the 25th) as share pricing jumps +$0.03 with 3,273 shares traded on 4/25/25 ... Who's buying a falling knife ... fork and spoon after barely if any trading volume for months -- DST Capital? New: On April 11, 2025, Marcum LLP (their accountants) informed Harvard Apparatus Regenerative Technology (OTCQB: HRGN) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 11, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm. Marcum’s LLP had reported the addition of a paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. Following a MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? Under the Holding Foreign Companies Accountable Act, the SEC can ban foreign companies from trading ..." Wall Street Journal, 4/21/25 ... "Many investors would opt to SELL their stakes in Chinese firms if they are delisted" March 10, 2025 Beam Therapeutics (BEAM) an offering of 16,151,686 shares priced at $28.48 per share including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525 February 18, 2025 RegMedInvestors (RMi) Financing Note: Solid Biosciences (SLDB) priced 35.739 M share offering with warrants 35.739 M shares were priced at $4.30 with 13.88 M warrants priced at $4.029 Tuesday SLDB jumped +$1.27 to $5.30 The financing includes new and existing investors, including Adage Capital Partners LP, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, TCGX, Venrock Healthcare Capital Partners, Vestal Point Capital, a U.S.-based life-sciences focused institutional investor, a major mutual fund and a large investment management firm. January 27, 2025 RegMedInvestors (RMi):Sage Therapeutics (SAGE) has unanimously rejected Biogen’s (BIIB) $469 M offer Breaking: SAGE board has unanimously rejected Biogen’s (BIIB) $469 M offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests. BIIB, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. SAGE also announced it has initiated a process to explore strategic alternatives but has not set a timeline for the review. SAGE confirmed (2/10/25) that Biogen (BIIB) has submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of SAGE not already owned by BIIB for $7.22 per share. SAGE is trading (Monday, 1/27/25) up +$0.39 or -5.42% at $7.49

Indication intelligence, analysis and sector perception

Weekend Recap

Earnings